UPC Analytics
ENDE
Overview · Filed: Nov 8, 2024

UPC_CFI_681/2024

DATA PROCESSING, ANALYSIS METHOD OF GENE EXPRESSION DATA TO IDENTIFY ENDOGENOUS REFERENCE GENES

Parent infringement case:UPC_CFI_437/2024

RevocationCounter Claim for RevocationMunich LDCounter claim for revocationCase Closed
OverviewDecisionsReasoningCitationsDocumentsTimeline
Parties

Claimants

  • Myriad Genetics S.A.S.
  • Myriad International GmbH
  • Myriad Genetics GmbH
  • Myriad Genetics, Inc.
  • Myriad Genetics B.V.
  • Eurobio Scientific
  • Myriad Service GmbH
  • Myriad Genetics S.r.l.
  • Myriad GmbH
Reps: Rauh (Vossius & Brinkhof UPC Litigators)

Respondents

  • GXD-Bio Corporation
Reps: Hölder (Hoffmann Eitle)
Judges
  • Daniel Voss
  • Georg Werner
  • Marije Knijff
  • Cornelis Schüller
Patents
  • EP3346403
  • EP 3 346 403
CPC codes: G16B25/10, C12Q2600/166, C12Q1/6851, C12Q1/6813, G16B25/00, C40B40/06

Technology area: Biotech · Genomics

Sector: Biotechnology

Outcome
Not infringedDismissed
Filed: Nov 8, 2024
First decided: Dec 19, 2025
Language: English

The Munich Local Division dismissed both the infringement action (UPC_CFI_437/2024) brought by GXD-Bio Corporation and the counterclaim for revocation (UPC_CFI_681/2024) brought by the Myriad defendants, concerning EP 3 346 403 (a patent on data processing/gene expression analysis for identifying endogenous reference genes). The Court found no infringement because the accused products (Myriad test kits) did not use the claimed three-step normalization method — the products used a single-step average normalization that differed from the patented calculation method. The counterclaim for revocation was also dismissed, so the patent was maintained. Each party bears its own costs, with costs capped at EUR 600,000 total.

Open on UPC Registry
Claims
At issueall
Maintainedall
Not infringedall
Notes: Infringement action dismissed (no infringement of EP 3 346 403 three-step normalization method) and counterclaim for revocation also dismissed, patent maintained.